Metabolic syndrome in schizophrenia

Indian Journal of Psychological Medicine

Volumn 35, Issue 3, 2013, Pages 227-240

  Malhotra, Nidhi ^a   Grover, Sandeep ^a   Chakrabarti, Subho ^a   Kulhara, Parmanand ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Cardiovascular risk; metabolic syndrome; schizophrenia

Indexed keywords

EID: 84886235283     PISSN: 02537176     EISSN: 09751564     Source Type: Journal    
DOI: 10.4103/0253-7176.119471     Document Type: Article

References (134)

1. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123-31.
2. Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St Sauver J. Mortality in schizophrenia and schizoaffective disorder: An Olmsted County, Minnesota cohort: 1950-2005. Schizophr Res 2008;98:287-94.
3. Brown S. Excess mortality of schizophrenia. A meta-Analysis. Br J Psychiatry 1997;171:502-8.
4. Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res 2011;131:101-4.
5. Basu R, Brar JS, Chengappa KN, John V, Parepally H, Gershon S, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord 2004;6:314-8.
6. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002;26:137-41.
7. Kaneda Y, Fujii A, Ohmori T. The hypothalamic-pituitaryadrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:935-8.
8. Rosmond R. The glucocorticoid receptor gene and its association to metabolic syndrome. Obes Res 2002;10:1078-86.
9. Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. Biol Psychiatry 1999;46:1595-602.
10. Alméras N, Després JP, Villeneuve J, Demers MF, Roy MA, Cadrin C, et al. Development of an atherogenic metabolic risk profile associated with the use of atypical antipsychotics. J Clin Psychiatry 2004;65:557-64.
11. Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. CLAMORS Study Collaborative Group. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study. Schizophr Res 2008;104:1-12.
12. Azanza JR, Bernardo M, Rojo L, Rejas-Gutierrez J, Mesa F. Prevalence of metabolic syndrome in Spanish patients with schizophrenia and overweight. Eur Psychiatry 2009;24:S1163.
13. Bai YM, Lin CC, Chen JY, Chen TT, Su TP, Chou P. Association of weight gain and metabolic syndrome in patients taking clozapine: An 8-year cohort study. J Clin Psychiatry 2011;72:751-6.
14. Baptista T, Serrano A, Uzcátegui E, ElFakih Y, Rangel N, Carrizo E, et al. The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: Comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela. Schizophr Res 2011;126:93-102.
15. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. CLAMORS Study Collaborative Group. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study. Schizophr Res 2007;90:162-73.
16. Boke O, Aker S, Sarisoy G, Saricicek EB, Sahin AR. Prevalence of metabolic syndrome among inpatients with schizophrenia. Int J Psychiatry Med 2008;38:103-12.
17. Bernardo M, Cañas F, Banegas JR, Casademont J, Riesgo Y, Varela C. RICAVA Study Group. Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: A cross-sectional study in a low cardiovascular disease risk geographical area. Eur Psychiatry 2009;24:431-41.
18. Brunero S, Lamont S, Fairbrother G. Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia. Arch Psychiatr Nurs 2009;23:261-8.
19. Cerit C, Özten E, Yildiz M. The prevalence of metabolic syndrome and related factors in patients with schizophrenia. Turk Psikiyatri Derg 2008;19:124-32.
20. Cerit C, Vural M, Bos Gelmez SÜ, Ozten E, Aker AT, Yildiz M. Metabolic syndrome with different antipsychotics: A multicentre cross-sectional study. Psychopharmacol Bull 2010;43:22-36.
21. Cohn T, Prud́homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: High prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753-60.
22. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007;89:91-100.
23. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008;10:788-97.
24. Correll CU, Druss BG, Lombardo I, O'Gorman C, Harnett JP, Sanders KN, et al. Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv 2010;61:892-8.
25. De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006;83:87-93.
26. De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: A cross-sectional study. Clin Pract Epidemiol Ment Health 2006;27:2-14.
27. De Hert M, Hanssens L, Wampers M. Prevalence and incidence rates of metabolic abnormalities and diabetes in a prospective study of patients treated with second-generation antipsychotics. Schizophr Bull 2007;33:560.
28. De Hert M, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, et al. The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology. Int J Methods Psychiatr Res 2010;19:195-210.
29. Ellingrod VL, Miller DD, Taylor SF, Moline J, Holman T, Kerr J. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTH-FR) 677C/T and 1298A/C variants. Schizophr Res 2008;98:47-54.
30. Ellingrod VL, Taylor SF, Dalack G, Grove TB, Bly MJ, Brook RD, et al. Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: The role of folate pharmacogenetics. J Clin Psychopharmacol 2012;32:261-5.
31. Fan X, Liu EY, Freudenreich O, Park JH, Liu D, Wang J, et al. Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophr Res 2010;118:211-7.
32. Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, et al. The METEOR study: Frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol 2011;26:291-302.
33. Ferreira L, Belo A, Abreu-Lima C. RICAVA study group. A case-control study of cardiovascular risk factors and cardiovascular risk among patients with schizophrenia in a country in the low cardiovascular risk region of Europe. Rev Port Cardiol 2010;29:1481-93.
34. Gordon PC, Xavier JC, Louzã MR. Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia. Neuropsychiatr Dis Treat 2013;9:133-8.
35. Grover S, Nebhinani N, Chakrabarti S, Avasthi A, Kulhara P. Metabolic syndrome among patients receiving clozapine: A preliminary estimate. Indian J Pharmacol 2011;43:591-5.
36. Grover S, Aggarwal M, Dutt A, Chakrabarti S, Avasthi A, Kulhara P, et al. Prevalence of metabolic syndrome in patients with schizophrenia in India. Psychiatry Res 2012;200:1035-7.
37. Grover S, Nebhinani N, Chakrabarti S, Avasthi A, Kulhara P, Basu D, et al. Comparative study of prevalence of metabolic syndrome in bipolar disorder and schizophrenia from North India. Nord J Psychiatry 2013.
38. Gulzar M, Rafiq A, OCuill M. Prevalence of metabolic syndrome in elderly schizophrenic patients in Ireland. Eur Arch Psychiatry Clin Neurosci 2009;259 Suppl 1:S85.
39. Güveli H, Cem IM, Yener F, Karamustafalioǧlu N, Ipekçioǧlu D, Abanoz Z. The frequency of metabolic syndrome in schizophrenia patients using antipsychotic medication and related factors. Yeni Symp 2011;49:67-76.
40. Hatata H, El-Gohary G, Abd-Elsalam M, Elokda E. Risk Factors of Metabolic Syndrome among egyptian patients with schizophrenia. Curr Psychiatry 2009;16:85-95.
41. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006;21:93-8.
42. Hanssens L, van Winkel R, Wampers M, Van Eyck D, Scheen A, Reginster JY, et al. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res 2008;106:308-14.
43. Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-9.
44. Huang MC, Lu ML, Tsai CJ, Chen PY, Chiu CC, Jian DL, et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 2009;120:274-80.
45. James BO, Lawani AA, Okolo M, Morakinyo O. Prevalence of the metabolic syndrome among schizophrenia patients on antipsychotics in Nigeria. Schizophr Res 2010;117:2-3.
46. Kagal UA, Torgal SS, Patil NM, Malleshappa A. Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents-A cross-sectional study. J Pharm Pract 2012;25:368-73.
47. Kang SH, Kim KH, Kang GY, Lee KH, Kim KK, Soh M, et al. Cross-sectional prevalence of metabolic syndrome in Korean population with schizophrenia. Schizophr Res 2011;128:179-81.
48. Kang SH, Lee JI, Chang AK, Joo YH, Kim CY, Kim SY. Genetic polymorphisms in the HTR2C and peroxisome proliferator-Activated receptors are not associated with metabolic syndrome in patients with schizophrenia taking clozapine. Psychiatry Investig 2011;8:262-8.
49. Kato MM, Currier MB, Gomez CM, Hall L, Gonzalez-Blanco M. Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry 2004;6:74-7.
50. Kim CH, Nam YY, Ahn CW. Clinical correlates of metabolic syndrome in patients with chronic schizophrenia. Schiophr Res 2008;102:242-3.
51. Krane-Gartiser K, Breum L, Glümrr C, Linneberg A, Madsen M, Køster A, et al. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry 2011;65:345-52.
52. Kaya MC, Virit O, Altindag A, Selek S, Bülbül F, Bulut M, et al. Prevalence of metabolic syndrome, characteristics of metabolic syndrome and relationship with the antipsychotics used in schizophrenia. Nöropsikiyatri Arşivi 2009;46:13.
53. Kurt E, Altinbas K, Alatas G, Ozver I. Metabolic syndrome prevalence among schizophrenic patients treated in chronic inpatient clinics. Türkiye'de Psikiyatri 2007;9:141-5.
54. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006;7:1273-6.
55. Larsen JT, Fagerquist M, Holdrup M, Christensen B, Sigalin C, Nilsson PM. Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden. Nord J Psychiatry 2011;65:40-6.
56. Lee NY, Kim SH, Jung DC, Kim EY, Yu HY, Sung KH, et al. The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1273-8.
57. Lee J, Nurjono M, Wong A, Salim A. Prevalence of metabolic syndrome among patients with schizophrenia in Singapore. Ann Acad Med Singapore 2012;41:457-62.
58. Lee NY, Roh MS, Kim SH, Jung DC, Yu HY, Sung KH, et al. The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia. Int Clin Psychopharmacol 2013;28:71-9.
59. Lindenmayer JP, Khan A, Kaushik S, Thanju A, Praveen R, Hoffman L, et al. Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophr Res 2012;142:171-6.
60. Lin CC, Yu SC, Wu BJ, Chang DJ. Measurement of waist circumference at different sites affects the detection of abdominal obesity and metabolic syndrome among psychiatric patients. Psychiatry Res 2012;197:322-6.
61. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32.
62. Maslov B, Marcinko D, Milicevic R, Babić D, Dordević V, Jakovljević M. Metabolic syndrome, anxiety, depression and suicidal tendencies in post-traumatic stress disorder and schizophrenic patients. Coll Antropol 2009;33:7-10.
63. Medeiros-Ferreira L, Obiols JE, Navarro-Pastor JB, Zuniga-Lagares A. Metabolic syndrome and health-related quality of life in patients with schizophrenia. Actas Esp Psiquiatr 2013;41:17-26.
64. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005;80:9-18.
65. Meyer J, Loh C, Leckband SG, Boyd JA, Wirshing WC, Pierre JM, et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract 2006;12:5-10.
66. Misawa F, Shimizu K, Fujii Y, Miyata R, Koshiishi F, Kobayashi M, et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: A cross-sectional study. BMC Psychiatry 2011;11:118.
67. Nurjono M, Lee J. Predictive utility of blood pressure, waist circumference and body mass index for metabolic syndrome in patients with schizophrenia in Singapore. Early Interv Psychiatry 2013;7:205-9.
68. Oyekcin DG. The frequency of metabolic syndrome in patients with schizophrenia and schizoaffective disorder. Anatolian J Psychiatry 2009;10:26-33.
69. Phutane VH, Tek C, Chwastiak L, Ratliff JC, Ozyuksel B, Woods SW, et al. Cardiovascular risk in a first-episode psychosis sample: A 'critical period́ for prevention?Schizophr Res 2011;127:257-61.
70. Rahman AH, Asmara HS, Baharudin A, Sidi H. Metabolic syndrome in psychiatric patients with primary psychotic and mood disorders. Asean J Psychiatry 2009;10:1-8.
71. Rejas J, Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M. Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: A corollary from the CLAMORS study. Schizophr Res 2008;99:23-8.
72. Rivas-Vazquez RA, Bello I, Sarria M, Fernandez ND, Rey GJ. Prevalence of metabolic syndrome in a predominantly cuban, psychiatrically ill, and homeless population. Prim Care Companion CNS Disord 2011;13.
73. Rezaei O, Khodaie-Ardakani MR, Mandegar MH, Dogmehchi E, Goodarzynejad H. Prevalence of metabolic syndrome among an Iranian cohort of inpatients with schizophrenia. Int J Psychiatry Med 2009;39:451-62.
74. Roshdy R. Prevalence of metabolic syndrome in patients with schizophrenia. Middle East Curr Psychiatry 2011;18:109-17
75. Said MA, Sulaiman AH, Habil MH, Das S, Bakar AK, Yusoff RM, et al. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia. Singapore Med J 2012;53:801-7.
76. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin MR, Lauren LH, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: The northern Finland 1966 birth cohort study. J Clin Psychiatry 2005;66:559-63.
77. Schorr SG, Lucas M, Slooff CJ, Bruggeman R, Taxis K. The prevalence of metabolic syndrome in schizophrenic patients in the Netherlands. Schizophr Res 2008;102 (Suppl 2):241.
78. Schorr SG, Slooff CJ, Bruggeman R, Taxis K. The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res 2009;43:1106-11.
79. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N. Metabolic syndrome in Thai schizophrenic patients: A naturalistic one year follow-up study. BMC Psychiatry 2007;23:7-14.
80. Sicras A, Rejas J, Navarro R, Serrat J, Blanca M. Metabolic syndrome in bipolar disorder: A cross-sectional assessment of a Health Management Organization database. Bipolar Disord 2008;10:607-16.
81. Subashini R, Deepa M, Padmavati R, Thara R, Mohan V. Prevalence of diabetes, obesity, and metabolic syndrome in subjects with and without schizophrenia (CURES-104). J Postgrad Med 2011;57:272-7.
82. Straker D, Correll CU, Kramer-Ginsberg E, Abdulhamid N, Koshy F, Rubens E, et al. Cost-effective screening for the metabolic syndrome in patients treated with second generation antipsychotic medications. Am J Psychiatry 2005;162:1217-21.
83. Sugawara N, Yasui-Furukori N, Sato Y, Umeda T, Kishida I, Yamashita H, et al. Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res 2010;123:244-50.
84. Sugawara N, Yasui-Furukori N, Sato Y, Kishida I, Yamashita H, Saito M, et al. Comparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia. Ann Gen Psychiatry 2011;10:21.
85. Suvisaari JM, Saarni SI, Perala J, Suvisaari JV, Harkanen T, Lonnqvist J, et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007;68:1045-55.
86. Steylen PM, van der Heijden FF, Verhoeven W, Kok JD, van Soest M, Tuinier S. Metabolic syndrome during clozapine treatment. PW Wetenschappelijk Platform 2009; 3:96-100.
87. Sweileh WM, Zyoud SH, Dalal SA, Ibwini S, Sawalha AF, Ali I. Prevalence of metabolic syndrome among patients with schizophrenia in Palestine. BMC Psychiatry 2012;12:235.
88. Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007;29:330-6.
89. Tirupati S, Chua LE. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust N Z J Psychiatry 2007;41:606-10.
90. Van Der Heijden F, Steylen P, Kok H, Slaar A, Verhoeven W. Low rates of treatment of cardiovascular risk factors in patients treated with antipsychotics. Eur Psychiatry 201;26.
91. van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res 2010; 121:193-8.
92. van Winkel R, van Os J, Celic I, Van Eyck D, Wampers M, Scheen A, et al. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: Results from a comprehensive, naturalistic screening program. J Clin Psychiatry 2008;69:1319-27.
93. Vancampfort D, Sweers K, Probst M, Maurissen K, Knapen J, Minguet P, et al. Association of the metabolic syndrome with physical activity performance in patients with schizophrenia. Diabetes Metab 2011;37:318-23.
94. Vuksan-Cusa B, Sagud M, Jakovljević M. C-reactive protein and metabolic syndrome in patients with bipolar disorder compared to patients with schizophrenia. Psychiatr Danub 2010;22:275-7.
95. Yazici MK, Anil Yaǧcioǧlu AE, Ertuǧrul A, Eni N, Karahan S, Karaaǧaoǧlu E, et al. The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: Findings from a cohort in Turkey. Eur Arch Psychiatry Clin Neurosci 2011;261:69-78.
96. Yoon BH, Bae A, Bahk WM. Prevalence and characteristics of metabolic syndrome in schizophrenic inpatients. Schizophr Res 2008;102:244.
97. Padmawati R, McCreadle RG, Tirupati S. Low prevalence of obesity and metabolic syndrome in never treated chronic schizophrenia. Schizophr Res 2010;121:199-202.
98. Pallava A, Chadda RK, Sood M, Lakshmy R. Metabolic syndrome in schizophrenia: A comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India. Nord J Psychiatry 2012;66:215-21.
99. Grover S, Nebhinani N, Chakrabarti S, Parakh P, Ghormode D. Metabolic syndrome in antipsychotic naïve patients diagnosed with schizophrenia. Early Interv Psychiatry 2012;6:326-31.
100. Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, et al. Metabolic side effects of risperidone in early onset schizophrenia. Encephale 2010;36:242-52.
101. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophr Res 2008;101:295-303.
102. Medved V, Kuzman MR, Jovanovic N, Grubisin J, Kuzman T. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: A 3-month follow-up. J Psychopharmacol 2009;23:915-22.
103. Saddichha S, Ameen S, Akhtar S. Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: A six-week prospective study in Indian female patients. Schizophr Res 2007;95:247.
104. Sahoo S, Ameen S, Akhtar S. Metabolic syndrome in drug-naive first episode psychosis treated with atypical antipsychotics. Aust N Z J Psychiatry 2007;41:629.
105. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia-A randomized double-blind controlled, short-term prospective study. Schizophr Res 2008;101:266-72.
106. Attux C, Quintana MI, Chaves AC. Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic metabolic syndrome on first episode psychotic patients after six-month follow-up. Rev Bras Psiquiat 2007;29:346-9.
107. Chiu CC, Chen CH, Chen BY, Yu SH, Lu ML. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:866-70.
108. Fleischhacker WW, Siu CO, Bodén R, Pappadopulos E, Karayal ON, Kahn RS. The EUFEST study group. Metabolic risk factors in first-episode schizophrenia: Baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Neuropsychopharmacol 2013;16:987-95.
109. Gautam S, Meena PS. Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. Indian J Psychiatry 2011;53:128-33.
110. Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res 2009;110:95-102.
111. Kraemer S, Minarzyk A, Forst T, Kopf D, Hundemer HP. Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics-results from a german observational study. BMC Psychiatry 2011;11:173.
112. Lin CC, Bai YM, Wang YC, Chen TT, Lai IC, Chen JY, et al. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics. J Clin Psychopharmacol 2009;29:529-36.
113. Malhotra N, Kulhara P, Chakrabarti S, Grover S. A prospective, longitudinal study of metabolic syndrome in patients with bipolar disorder and schizophrenia. J Affect Disord 2013.
114. Maayan LA, Vakhrusheva J. Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. Hum Psychopharmacol 2010;25:133-8.
115. Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Schizophr Res 2008;101:273-86.
116. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: Analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005;27:1930-41.
117. Nebhinani N, Grover S, Chakrabarti S, Kate N, Avasthi A. A longitudinal study of change in prevalence of metabolic syndrome and metabolic disturbances 3 months after Clozapine therapy. Journal of Mental Health and Human Behavior 2013;18:9-17.
118. Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, et al. CAFE Investigators. Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the café study. Schizophr Res 2009;111:9-16.
119. Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 2012;37:1901-11.
120. Na KS, Kim WH, Jung HY, Ryu SG, Min KJ, Park KC, et al. Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012;39:295-300.
121. Miller BJ, Mellor A, Buckley P. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-Affective psychoses. Brain Behav Immun 2012.
122. Lee K, Park J, Choi J, Park CG. Heart rate variability and metabolic syndrome in hospitalized patients with schizophrenia. J Korean Acad Nurs 2011;41:788-94.
123. Cheng C, Chiu HJ, Loh el-W, Chan CH, Hwu TM, Liu YR, et al. Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36:205-10.
124. Risselada AJ, Vehof J, Bruggeman R, Wilffert B, Cohen D, Al Hadithy AF, et al. Association between the 1291-C/G polymorphism in the adrenergic á-2a receptor and the metabolic syndrome. J Clin Psychopharmacol 2010;30:667-71.
125. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
126. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-A new worldwide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469-80.
127. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Geneva: World Health Organisation; 1999.
128. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3.
129. American College of Endocrinology Task Force on the insulin resistance syndrome. Endocr Pract 2003;9:236-52.
130. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol 2005;4:198-203.
131. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. International Diabetes Federation Task Force on Epidemiology and Prevention, Hational Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity. Harmonizing the Metabolic Syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute; American Heart Association, World Heart Federation, International Atherosclerosis Society, and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
132. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003;24:987-1003.
133. Wilson PW, D́Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
134. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006;67:575-83.